Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Source: 
Clinical Trials Arena
snippet: 

Novartis has announced positive data from a Phase III trial investigating iptacopan in patients with paroxysmal nocturnal haemoglobinuria (PNH). The study met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints.